Clinical Trial: A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07116616) titled 'A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma' on Aug. 07.

Brief Summary: The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL

Condition: Relapsed or Refractory Multiple Myeloma

Intervention: DRUG: mRNA-2808

intravenous

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ModernaTX, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....